Biogenesis Bago

What Biogenesis Bago does

Biogénesis Bagó S.A. is an Argentine-domiciled animal health biotechnology company that develops, manufactures, and commercializes vaccines, pharmaceuticals, reproductive hormones, and nutraceuticals for livestock and companion animals across more than 60 countries. The company is the largest veterinary vaccine producer in Latin America and the fifth-largest globally in pet vaccine production capacity, anchored by its proprietary BIOAFTOGEN® foot-and-mouth disease (FMD) vaccine — the first product worldwide to obtain prequalification from the European Commission for the Control of Foot-and-Mouth Disease (EuFMD/FAO) — and a high-potency SAT 1/SAT 2/SAT 3 FMD vaccine line. Its core technical differentiator is a liquid-nitrogen cryopreservation system for concentrated viral antigens (described as unique in Latin America for animal health) that enables emergency vaccine production within 5–6 days versus the industry standard of roughly three months, making the company a designated operator of national antigen and vaccine banks for Argentina (SENASA, since 2000), the United States and Canada (USDA North American FMD Vaccine Bank, since 2006), Taiwan, South Korea, and now Brazil (via Tecpar, 2025). Beyond FMD, the company supplies more than 140 million doses of canine rabies vaccine to 15 countries via the Pan American Health Organization Revolving Fund, and operates a 200+ product pet health portfolio assembled through the acquisitions of Laboratorio Mayors (2022), HIPRA's reproduction hormone line (Gestavet family, 2022), and Mundo Animal (January 2025).

The company's business model is a hybrid of direct enterprise sales to government animal-health authorities and large livestock producers, channel partnerships with local veterinary distributors, and licensing/royalty revenue from technology-transfer arrangements that build local FMD and rabies vaccine manufacturing capacity in countries including Brazil, Saudi Arabia, and South Korea. Recurring revenue is generated through multi-year antigen and vaccine bank contracts, with notable anchor agreements including a 10-year Brazil arrangement covering 10 million antigen doses plus an immediate 10 million-dose vaccine supply. The operating footprint comprises seven production plants across Argentina, Brazil, China, South Korea, and Saudi Arabia, supported by 12 commercial offices in Latin America, Europe, Asia, and the Middle East; total headcount exceeds 1,300 across an interdisciplinary multinational team. Biogénesis Bagó is a subsidiary of the Argentine Bagó Group and discloses no external equity funding rounds, suggesting the recent acquisition-led expansion (seven transactions over five years) has been financed through parent-group balance sheet capacity and operating cash flow. The company's stated objective is to rank among the top 20 global animal health companies by 2026.

Name

Biogenesis Bago

Legal name

BIOGÉNESIS BAGÓ S.A.

Website

https://biogenesisbago.com

Company type

Private

Founded year

2000

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Biogénesis Bagó is an Argentine animal health biotechnology company that develops, manufactures, and commercializes FMD and rabies vaccines, pharmaceuticals, reproductive hormones, and nutraceuticals for livestock and companion animals across 60+ countries.

Ownership category

akta.pro rank

Product category

Veterinary Biologics and Animal Health Pharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Veterinary Vaccines (Biologics) (HLAMAEAL)

akta.pro secondary industries

Vaccine Manufacturing & Contract Services (Veterinary Vaccine CDMO) (HLAMAKAI), Vaccine R&D, Clinical/Field Trials & Regulatory Affairs (HLAMAKAM), Vaccine Programs & Tendering (Government/NGO, Eradication Campaigns) (HLAMAKAO), Companion Animal Vaccines (Dogs & Cats) (HLAMAKAA), Veterinary Pharmacy, Vaccine & Biologics Services (AFAEANAK), Veterinary Vaccines (HLAIAEAH)

Keywords

• Veterinary vaccines
• Animal health products
• Foot-and-mouth disease vaccines
• Livestock pharmaceuticals
• Biotechnology manufacturing

Headquarters

HQ city

Garín

HQ country

Argentina

HQ region

Latin America

Offices17 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Vaccine Sales: Sale of foot-and-mouth disease vaccines, rabies vaccines, and companion animal vaccines to governments, distributors, and veterinary practices across 60+ countries. Major supplier to Pan American Health Organization for rabies vaccines.
2. Pharmaceutical and Antiparasitic Products: Sale of pharmaceutical products including antibiotics, anti-parasitics, anti-arthritic, gastric protectors, dermatological solutions, vitamins, and minerals for livestock and companion animals.
3. Reproductive Hormone Products: Sale of hormone products and solutions for animal reproduction including Gestavet product line, FTAI hormones, and reproductive technologies for cattle, swine, and small ruminants.
4. Technology Transfer Services: Technology transfer services for construction of FMD vaccine manufacturing sites (Saudi Arabia, South Korea) and rabies vaccine production (Brazil via Tecpar), including training and know-how licensing.
5. Antigen Bank Supply Contracts: Long-term supply contracts for national antigen and vaccine banks including Brazil (10-year agreement for 10 million doses), USA, Canada, Taiwan, and South Korea, providing recurring revenue from strategic government partnerships.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels4 records

Core offering

Biogénesis Bagó researches, develops, manufactures, and commercializes veterinary biologics and pharmaceuticals for livestock and companion animals. Its core offering centers on foot-and-mouth disease (FMD) vaccines, rabies vaccines, antiparasitics, reproductive hormones, antibiotics, and nutraceuticals, supported by proprietary antigen cryopreservation technology enabling emergency vaccine production. The company also provides technology transfer services and supplies strategic antigen banks to governments across multiple continents.

Product overview

Biogénesis Bagó is a global biotechnology company offering a comprehensive portfolio of animal health products and services for livestock and companion animals. The product portfolio includes core vaccine products (BIOAFTOGEN FMD vaccines, rabies vaccines), pharmaceutical products (antibiotics, anti-parasitics, anti-arthritics, dermatological solutions, gastric protectors), reproductive solutions (Gestavet hormone product line), and supplements. The company operates through multiple production facilities across Argentina, Brazil, China, and other countries, with products distributed across 60+ countries in the Americas, Asia, Europe, Middle East, and North Africa. Recent acquisitions (Mayors Laboratory, Mundo Animal, HIPRA reproduction products) have expanded the portfolio to over 200 pet care solutions. Key products include BIOAFTOGEN (FMD vaccine prequalified by EuFMD/FAO), rabies vaccines (supplied to Pan American Health Organization), Gestavet reproductive hormones, and various pharmaceutical and antiparasitic products.

Differentiator

Problem solved

Functional benefit

Brands

• Gestavet: Hormonal products for animal reproduction including Gestavet, Gestavet Prost, Gestavet GnRH, Gonaser and Esponjavet
• BIOAFTOGEN
• AFTOGEN OLEO
• BioVademécum

Products and services

• BIOAFTOGEN Foot-and-mouth disease vaccine, first in the world to obtain prequalification from EuFMD (European Commission for the Control of FMD). Provides protection for cattle, buffaloes, goats, sheep, and pigs, exported in nine formulations to 27 countries.
• Rabies Vaccine High-quality rabies vaccine for dogs and cats. Biogénesis Bagó is the main supplier of canine rabies vaccine to the Pan American Health Organization, having supplied over 140 million doses to 15 countries since 2012.
• AFTOGEN OLEO High-potency FMD vaccine for quick and long-lasting immunity across species, used for outbreak control including Indonesia (2022).
• Gestavet Product Line Complete line of hormone products for animal reproduction including Gestavet, Gestavet Prost, Gestavet GnRH, Gonaser, and Esponjavet. Covers cattle, swine, and small ruminants reproduction solutions, acquired from HIPRA.
• Antiparasitics Anti-parasitic products for livestock and companion animals.
• Pharmaceuticals Pharmaceutical products including antibiotics (beta-lactams), gastric protectors, and anti-arthritic treatments for animals.
• Supplements and Nutraceuticals Vitamin, mineral, and nutritional supplement products for animals.
• Reproductive Products Hormone products for animal reproduction including FTAI (Fixed Time Artificial Insemination) hormones and reproductive solutions.
• Mayors Laboratory Products Pharmaceutical products for companion animals including anti-arthritic, anti-parasiticides, gastric protectors, and dermatological solutions. Products sold in 16 countries in Latin America and Middle East, acquired from Mayors Laboratory.
• Mundo Animal Products Solutions for pet nutrition, medicine, and hygiene developed at manufacturing site in Pindamonhangaba, São Paulo, Brazil. Complements existing portfolio creating over 200 solutions for the pet segment globally, acquired from Mundo Animal.
• Live Attenuated Virus (MLV) Vaccines MLV vaccines for companion animals and livestock including 3-in-1, 5-in-1/6-in-1 vaccines for cats. Produced at Campo Largo Brazil facility with annual capacity over 10 million doses.
• Hygiene and Skin Health Products Products for hygiene and skin health care for animals.

Quantifiable outcome

• Emergency FMD vaccine production in 5-6 days using cryopreserved antigen bank technology
• +4 more outcomes

Named customers7 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Ten partnerships are on record, tiered core and minor.

• Government of South AfricacoreStrategic or Co-development Partner · 1 January 2026Supply agreement for 1 million initial FMD vaccine doses (with additional 5 million pending regulatory approval) against SAT 1, SAT 2, and SAT 3 strains. Vaccines integrated into massive national vaccination campaign targeting 80%+ coverage of 14 million cattle.
• Botswana Vaccine InstituteminorChannel Partner/ Reseller/ Distributor · 1 January 2026Government of South Africa sourced 2 million vaccines from Botswana Vaccine Institute as part of coordinated national vaccination strategy.
• Paraná Technological Institute (Tecpar)coreStrategic or Co-development Partner · 1 March 2025Technology transfer agreement for creation of Brazil's first national FMD antigen and vaccine bank; Biogénesis Bagó supplies antigens while Tecpar formulates and distributes emergency vaccines nationwide within 72 hours. 10-year agreement covering 10 million doses of antigens from two FMD serotypes plus immediate supply of up to 10 million vaccine doses.
• ElancominorChannel Partner/ Reseller/ Distributor · 1 November 2024Partnership for FMD vaccine (Bioaftogen) launch in Indonesian market.
• CVG Tech and Advance PharmaminorChannel Partner/ Reseller/ Distributor · 1 October 2024Partnership for FMD vaccine (Bioaftogen) launch in Thai market.
• Arab Centre for Studies of Arid Zones and Dry Lands (ACSAD)minorStrategic or Co-development Partner · 1 January 2024Memorandum of Understanding signed to collaborate on improving livestock productivity across the Middle East, leveraging Biogénesis Bagó's FMD expertise.
• Fundación Mundo SanominorStrategic or Co-development Partner · 1 January 2024Collaboration on rabies vaccination campaigns across Argentina; joint public health initiatives to address rabies as a preventable disease.
• Global Alliance for Rabies ControlminorStrategic or Co-development Partner · 1 January 2024Supporting the 'End Rabies Now' campaign and related actions as part of FAO-OIE-WHO initiative.
• TECPAR (Brazil)coreStrategic or Co-development Partner · 1 January 2024Technology transfer agreement for rabies vaccine production in Brazil, first technology transfer project of its kind in the country.
• HIPRA (Spain)coreStrategic or Co-development Partner · 1 November 2022Acquisition of complete portfolio of hormone products for animal reproduction including brands Gestavet, Gestavet Prost, Gestavet GnRH, Gonaser, and Esponjavet. Enables entry into European market and 30 new countries; positions Biogénesis Bagó as global leader in reproduction for cattle, swine, and small ruminants.

Scale indicators14 records

Recent moves6 records

Expansion highlights7 records

Direct peers

• Ceva Santé Animale: France-based global animal health company focused on vaccines, pharmaceuticals, and biologicals for livestock and companion animals. Closely comparable mid-sized competitor with similar geographic reach and vaccine-led business model.
• HIPRA: Spanish animal health biotechnology company specializing in veterinary vaccines and pharmaceuticals for livestock and companion animals. Direct competitor in the FMD and reproductive hormone segments and historically a counterpart whose product line Biogénesis Bagó partially acquired.
• Botswana Vaccine Institute: African veterinary vaccine manufacturer specializing in FMD and livestock vaccines for SAT strains. Directly comparable as an FMD-focused player; referenced in source data as a competing supplier for the South Africa vaccination campaign.

Others

• Elanco Animal Health: Global animal health company with a strong livestock vaccine and therapeutic portfolio. Already a distribution partner of Biogénesis Bagó for the Bioaftogen launch in Indonesia and a competitor in broader FMD and companion animal categories.

Broad incumbents

• Virbac: France-based global animal health company focused on vaccines, parasiticides, and pharmaceuticals for livestock and companion animals. Comparable breadth in companion animal and livestock segments and a competitor in Latin American pet health markets.
• Vetoquinol: France-based global animal health company with a portfolio of pharmaceuticals and biologicals for livestock and pets. Comparable as a mid-sized European-rooted animal health company competing in pet pharma and livestock therapeutic categories.
• MSD Animal Health (Merck Animal Health): Global animal health division of Merck offering vaccines, anti-infectives, and parasiticides for livestock and companion animals. Competes in the FMD vaccine category globally and is a reference point for the scale Biogénesis Bagó is targeting.
• Zoetis: Global leader in animal health medicines, vaccines, and diagnostics, with a portfolio covering livestock and companion animals. Operates broadly across the same vaccine and pharmaceutical categories as Biogénesis Bagó but at vastly larger scale; key competitor for government tenders.
• Boehringer Ingelheim Animal Health: One of the top global animal health companies with a comprehensive vaccine, parasiticide, and therapeutics portfolio for livestock and pets. Competes with Biogénesis Bagó in FMD vaccines and broader veterinary biologics categories, particularly in Latin America.

Emerging players

• Indian Immunologicals: India-based veterinary vaccine manufacturer with a portfolio spanning livestock and companion animal vaccines, including FMD. Comparable as an emerging-market, vaccine-focused animal health company with government-tender exposure in its home region.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xtwitter.com/biogenesisbago?lang=en
• YouTubeyoutube.com/@BiogenesisBagoAR
• Facebookfacebook.com/BiogenesisBagoAr
• LinkedInar.linkedin.com/company/biogenesisbago
• Instagraminstagram.com/biogenesisbagoar

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Biogenesis Bago